ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial

Supported by Brain Resource, Ltd.Dr. Schatzberg has served as a consultant to Bay City Capital, BrainCells, CeNeRx, Cervel, Depomed, Eli Lilly, Forum, Genentech, Gilead, Jazz, Lundbeck/Takeda, McKinsey, Merck, MSI, Neuronetics, Novadel, One-Carbon, PharmaNeuroBoost, Sunovion, Synosia, and Xhale; he has received honoraria from Merck; he has equity in Amnestix, BrainCells, CeNeRx, Corcept (co-founder), Delpor, Forest, Merck, Neurocrine, Novadel, Pfizer, PharmaNeuroBoost, Somaxon, Synosis, Titan, and Xhale; and he receives royalties from Stanford University for patents on mifepristone use and the pharmacogenetics of antidepressant response. Dr. DeBattista has received research funding from Assurex, Brain Resource, Janssen, Takeda, and Roche and has served as a consultant for Genentech and Pfizer. Dr. Lazzeroni is named as an inventor on a genetics patent application filed by Stanford University. Dr. Etkin has received research funding from Brain Resource, Ltd. Dr. Murphy is named as an inventor on a patent application on genetic markers for antidepressant response filed by Stanford University; his contribution to the present work was done as a paid consultant for Brain Resource, Ltd., and was not part of his Stanford duties and responsibilities. Dr. Williams has received fees as a consultant for Brain Resource, Ltd., and has been a stockholder in Brain Resource, Ltd.